|
|
|
|
| LEADER |
04574nmm a2200325 u 4500 |
| 001 |
EB002065922 |
| 003 |
EBX01000000000000001206012 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
220901 ||| eng |
| 020 |
|
|
|a 9783030972202
|
| 100 |
1 |
|
|a Bekiş, Recep
|e [editor]
|
| 245 |
0 |
0 |
|a Radionuclide Therapy
|h Elektronische Ressource
|c edited by Recep Bekiş, Berna Polack, Murat Fani Bozkurt
|
| 250 |
|
|
|a 1st ed. 2022
|
| 260 |
|
|
|a Cham
|b Springer International Publishing
|c 2022, 2022
|
| 300 |
|
|
|a XXIII, 387 p. 122 illus., 101 illus. in color
|b online resource
|
| 505 |
0 |
|
|a Part-1: Basic Information. Basic properties and preparation of radiopharmaceuticals used in radionuclide therapy -- Physical Bases of Radionuclide Therapy (Biological Effects and Properties of Particle Radiation) -- Fundamentals of radiation safety and dosimetric approach in radionuclide therapy applications. Part-2: Clinical Information: Thyroid Diseases. Radionuclide Therapy in Benign Thyroid Diseases: Nodular Goiter Disease -- Radionuclide Therapy in Benign Thyroid Diseases: Graves' Disease -- Radionuclide Therapy in Malignant Thyroid Diseases: Differentiated Thyroid Cancer -- Radionuclide Therapy in Malignant Thyroid Diseases: Medullary Thyroid Cancer -- Systemic Treatments and related side effects in Thyroid Cancer. Part-2: Clinical Information: Neuroendocrine Tumors. Radionuclide Therapy in Neuroendocrine Tumors. Systemic Treatments and related side effects in Neuroendocrine Tumors. Part-4: Clinical Information: Neuroectodermal Tumors. Radionuclide Therapy in Neuroectodermal Tumors -- Systemic Treatments and related side effects in Neuroectodermal Tumors. Part-5: Clinical Information: Liver Tumors. Radionuclide Therapy in Liver Tumors. Systemic Treatments and related side effects in Liver Tumors. Part-6: Clinical Information: Prostate Cancer. Radionuclide Therapy in Prostate Cancer -- Systemic Treatments and related side effects in Prostate Cancer. Part-7: Clinical Information: Bone and Joint Diseases. Radionuclide Therapy in Joint Diseases: Radiosynovectomy -- Radionuclide Pain Palliation Therapy -- Radionuclide Therapy with Alpha Emitting Agents in Bone Metastases. Part-8: Clinical Information: Lymphoproliferative Diseases. Radionuclide Therapy in Lymphoproliferative Diseases. Part-9: Radioimmunotherapy. Basics and clinical applications of radioimmunotherapy. Part-10: Intracavitary Radionuclide Therapy. Intracavitaryradionuclide applications
|
| 653 |
|
|
|a Nuclear Medicine
|
| 653 |
|
|
|a Endocrinology
|
| 653 |
|
|
|a Gastroenterology
|
| 653 |
|
|
|a Nuclear medicine
|
| 653 |
|
|
|a Oncology
|
| 700 |
1 |
|
|a Polack, Berna
|e [editor]
|
| 700 |
1 |
|
|a Bozkurt, Murat Fani
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 028 |
5 |
0 |
|a 10.1007/978-3-030-97220-2
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-030-97220-2?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 6,160,757
|
| 520 |
|
|
|a The main purpose of this book is to create a reference for the indications, contraindications, patient selection, treatment practice, treatment side effect management, and follow-up of radionuclide treatments. Besides standard methods such as surgery, chemotherapy, radiotherapy, and hormone therapy, newly developed biological treatments, targeted treatments, personalized treatments, external beam radiotherapy, and targeted radionuclide treatments have begun to take their place in professional practice. Nuclear medicine, in addition to its role as a tracer of cancer, also assumes the role of treating with radioactive molecules directed to the cancer it traces. These traceable next-generation radionuclide treatments, whose efficacy and reliability have been proven and where diagnosis, treatment, and follow-up are carried out together, are increasingly included in oncology practice together with the new developed radiopharmaceuticals, ensuring a high rate of damage to cancer cells while protecting the surrounding normal tissues. Molecular cancer treatment will become more effective with individualized next-generation traceable radionuclide treatments, which will be shaped by genetic studies in the future. Radionuclide treatments for many cancer types and benign diseases are presented by experienced nuclear medicine experts in the light of their own experience and case studies, while systemic treatments in common cancer types and side effect management of these treatments are summarized by medical oncologists. This book will be of interest to nuclear medicine physicians as well as oncologists
|